Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Daily News

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Shelley Wood

December 02, 2016

News Features

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

Michael O'Riordan

October 05, 2016

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Cardiology Groups Applaud FDA’s Draft Guidance Setting Voluntary Sodium Cuts for Processed Food Industry

Shelley Wood

June 01, 2016

News Daily News

After Study Suggests Harm With Too-Low Sodium Intake, the American Heart Association Rebukes

Todd Neale

May 24, 2016

News Daily News

Nestlé Voluntarily Reducing Sodium in Processed Food, but Should the AHA Applaud?

Michael O'Riordan

May 09, 2016

News Industry News

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

January 31, 2016

News Conference News AHA 2015

SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients

Todd Neale

November 08, 2015

News Daily News

Recommendations Tackle Hypertension in CAD Patients

Todd Neale

April 03, 2015

News Daily News

Nitrite Injection May Be Cardioprotective in STEMI Patients With Low TIMI Flow

February 25, 2015

News Conference News TCT 2014

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Yael L. Maxwell

September 15, 2014

News Daily News

Initial Kidney Protection of Off-Pump CABG May Not Last

Caitlin E. Cox

June 04, 2014

News Conference News TCT 2013

BOSS: Sodium Bicarbonate May Protect Heart After Coronary Angiography

October 29, 2013

News Daily News

Antianginal Drug May Reduce Periprocedural MI in Elective PCI

Yael L. Maxwell

June 08, 2012

News Industry News

REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation

August 18, 2011

News Daily News

High Homocysteine Levels Linked with Contrast Nephropathy

Jason Kahn

July 28, 2011

News Conference News

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

Caitlin E. Cox

April 08, 2011

News Industry News

REMEDIAL II Trial of PLC's RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care

April 04, 2011

Advertisement

FDA Approves CV Death Reduction Claim for Empagliflozin in Type 2 Diabetes

Sodium Wars: Where Some See Linear Link With All-Cause Death, Others See No Need to Change Western Ways

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Cardiology Groups Applaud FDA’s Draft Guidance Setting Voluntary Sodium Cuts for Processed Food Industry

After Study Suggests Harm With Too-Low Sodium Intake, the American Heart Association Rebukes

Nestlé Voluntarily Reducing Sodium in Processed Food, but Should the AHA Applaud?

Mast Therapeutics Announces Positive Top-Line Results From Phase 2a Study Of AIR001 In Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) Conducted At Mayo Clinic

SPRINT Makes Case for Even Lower BP Target in Many Hypertensive Patients

Recommendations Tackle Hypertension in CAD Patients

Nitrite Injection May Be Cardioprotective in STEMI Patients With Low TIMI Flow

SYMPLICITY HTN-3 Substudy Examines BP Response Factors in African Americans

Initial Kidney Protection of Off-Pump CABG May Not Last

BOSS: Sodium Bicarbonate May Protect Heart After Coronary Angiography

Antianginal Drug May Reduce Periprocedural MI in Elective PCI

REMEDIAL II Trial of PLC's RenalGuard® Article Published in Circulation

High Homocysteine Levels Linked with Contrast Nephropathy

ACC Scientific Session-i2 Summit 2011: The Devil Is in the Details

REMEDIAL II Trial of PLC's RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content